Literature DB >> 27900097

Post-transplant lymphoproliferative disorder presenting with skin ulceration in a renal transplant recipient who achieved sustained remission with rituximab therapy: A case report.

Man Fai Law1, Hay Nun Chan2, Ho Kei Lai2, Chung Yin Ha2, Celia Ng2, Yiu Ming Yeung2, Sze Fai Yip2.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is associated with a variety of clinical presentations, but rarely involves the skin. We herein report a case of PTLD presenting with skin ulceration in a renal transplant recipient. A biopsy of the ulcer confirmed the diagnosis of diffuse large B-cell lymphoma. The patient was initially treated with immunosuppression reduction, but the skin ulcer persisted. He was then treated with two courses of chemotherapy, but his condition was complicated with cryptococcal infection. Antifungal agents were administered to control the fungal infection. The patient later developed lymphoma recurrence and was successfully treated with single-agent rituximab. The patient remains well 6 years after treatment, with no evidence of disease relapse. Therefore, PTLD may manifest as skin lesions and physicians must be aware of this rare presentation.

Entities:  

Keywords:  post-transplant lymphoproliferative disorder; rituximab; skin lesion

Year:  2016        PMID: 27900097      PMCID: PMC5103884          DOI: 10.3892/mco.2016.1024

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  14 in total

1.  Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients.

Authors:  Wing-Yan Au; Annie Pang; Carolyn Choy; Chor-Sang Chim; Yok-Lam Kwong
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

2.  Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

Authors:  S H K Oertel; E Verschuuren; P Reinke; K Zeidler; M Papp-Váry; N Babel; R U Trappe; S Jonas; M Hummel; I Anagnostopoulos; B Dörken; H B Riess
Journal:  Am J Transplant       Date:  2005-12       Impact factor: 8.086

Review 3.  II. Challenges in the management of post-transplant lymphoproliferative disorder.

Authors:  Luca Nassi; Gianluca Gaidano
Journal:  Hematol Oncol       Date:  2015-06       Impact factor: 5.271

Review 4.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 5.  The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis.

Authors:  J E Tanner; C Alfieri
Journal:  Transpl Infect Dis       Date:  2001-06       Impact factor: 2.228

6.  CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation.

Authors:  Sylvain Choquet; Ralf Trappe; Veronique Leblond; Ulrich Jäger; Frederic Davi; Stephan Oertel
Journal:  Haematologica       Date:  2007-02       Impact factor: 9.941

7.  Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

Authors:  Ralf Trappe; Stephan Oertel; Veronique Leblond; Peter Mollee; Monica Sender; Petra Reinke; Ruth Neuhaus; Hans Lehmkuhl; Heinz August Horst; Gilles Salles; Franck Morschhauser; Arnaud Jaccard; Thierry Lamy; Malte Leithäuser; Heiner Zimmermann; Ioannis Anagnostopoulos; Martine Raphael; Hanno Riess; Sylvain Choquet
Journal:  Lancet Oncol       Date:  2011-12-13       Impact factor: 41.316

8.  Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series.

Authors:  D Seçkin; S Barete; S Euvrard; C Francès; J Kanitakis; A Geusau; V Del Marmol; C A Harwood; C M Proby; I Ali; A T Güleç; E Durukan; C Lebbé; M Alaibac; E Laffitte; S Cooper; J N Bouwes Bavinck; G M Murphy; C Ferrándiz; C Mørk; P Cetkovská; W Kempf; G F L Hofbauer
Journal:  Am J Transplant       Date:  2013-05-29       Impact factor: 8.086

9.  Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors.

Authors:  Daan Dierickx; Thomas Tousseyn; Xavier Sagaert; Steffen Fieuws; Iwona Wlodarska; Julie Morscio; Lieselot Brepoels; Dirk Kuypers; Johan Vanhaecke; Frederik Nevens; Geert Verleden; Rita Van Damme-Lombaerts; Marleen Renard; Jacques Pirenne; Christiane De Wolf-Peeters; Gregor Verhoef
Journal:  Leuk Lymphoma       Date:  2013-04-09

10.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

Authors:  Ola Landgren; Ethel S Gilbert; J Douglas Rizzo; Gérard Socié; Peter M Banks; Kathleen A Sobocinski; Mary M Horowitz; Elaine S Jaffe; Douglas W Kingma; Lois B Travis; Mary E Flowers; Paul J Martin; H Joachim Deeg; Rochelle E Curtis
Journal:  Blood       Date:  2009-03-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.